Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
The Journal of the Acoustical Society of America|November 10, 2009
Long range sound propagation over a sea surfaceKarl Bolin, Mathieu Boué, Ilkka Karasalo
Therapie|July 10, 2016
Protocolisation, Use and Development of Anti-Cancer Drugs in the Context of T2A (Case-Mix Based Payment System) Set-UpAnne Mathieu-Boué, Pierre Demolis, Jean-François Bergmann, et al.
Therapie|November 28, 2006
Protocolisation, use and development of anti-cancer drugs in the context of T2A (case-mix based payment system) set-upAnne Mathieu-Boué, Pierre Demolis, Jean-François Bergmann
Anti-Cancer Drugs|June 13, 1998
Cytotoxic effect of interferon-alpha2a in combination with all-trans retinoic acid or cisplatin in human ovarian carcinoma cell linesS Jozan, M Courtade, A Mathieu-Boué, et al.
Cancer Research|December 15, 1994
Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patientsL P Rivory, E Chatelut, P Canal, et al.
Journal of Chromatography|March 27, 1992
Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patientsI Barilero, D Gandia, J P Armand, et al.
Cancer Research|June 15, 1993
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecinP J Houghton, P J Cheshire, J C Hallman, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urineF Lokiec, P Canal, C Gay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group studyD J Wagener, H E Verdonk, L Y Dirix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumorsG Catimel, G G Chabot, J P Guastalla, et al.
Pageof 2